Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)

Vasiliu,Octavian

doi:10.3892/etm.2023.11824

Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)

Authors:
- Octavian Vasiliu
View Affiliations

Affiliations: Department of Psychiatry, ‘Dr Carol Davila’ University Emergency Central Military Hospital, 010816 Bucharest, Romania
Published online on: February 6, 2023 https://doi.org/10.3892/etm.2023.11824
Article Number: 125
Copyright: © Vasiliu . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic dysfunctions have been reported in patients diagnosed with severe mental illnesses who are undergoing treatment with antipsychotics, especially second‑generation agents. Sodium‑glucose co‑transporter 2 inhibitors (SGLT2Is) and glucagon‑like peptide receptor agonists are new‑generation antidiabetics whose favourable effects in the treatment of diabetes mellitus in the non‑psychiatric population may raise interest in their use in patients presenting with severe mental illnesses and metabolic comorbidities possibly related to the use of antipsychotics. The objectives of this review were to investigate the evidence to support the use of SGLT2Is in this population and to find the most important aspects that need to be addressed by future research. A total of one preclinical trial, two guideline‑format clinical recommendations, one systematic review and one case report were found, and their conclusions were analysed. The results support the following conclusions: i) SGLT2Is may be combined with metformin in selected cases of type 2 diabetes mellitus in the context of antipsychotic treatment, as they have been associated with favourable metabolic effects; and ii) data for the recommendation of SGLT2Is as second‑line treatment in patients with diabetes mellitus who are also treated with olanzapine or clozapine are supported by very limited preclinical and clinical evidence. Further high‑quality, large‑scale research is needed in the field of the management of metabolic dysfunctions in patients with severe psychiatric illnesses who undergo treatment with second‑generation antipsychotics.

View Figures

View References

1	Cernea S, Dima L, Correll CU and Manu P: Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 80:1763–1781. 2020.PubMed/NCBI View Article : Google Scholar
2	Holt RIG: Association between antipsychotic medication use and diabetes. Curr Diab Rep. 19(96)2019.PubMed/NCBI View Article : Google Scholar
3	Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S and Howes OD: Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry. 74:261–269. 2017.PubMed/NCBI View Article : Google Scholar
4	Pillinger T, Beck K, Stubbs B and Howes OD: Cholesterol and triglyceride levels in first-episode psychosis: Systematic review and meta-analysis. Br J Psychiatry. 211:339–349. 2017.PubMed/NCBI View Article : Google Scholar
5	Teasdale SB, Ward PB, Jarman R, Wade T, Rossimel E, Curtis J, Lappin J, Watkins A and Samaras K: Is obesity in young people with psychosis a foregone conclusion? Markedly excessive energy intake is evident soon after antipsychotic initiation. Front Psychiatry. 9(725)2018.PubMed/NCBI View Article : Google Scholar
6	Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM and Leucht S: Head-to-head comparison of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res. 123:225–233. 2010.PubMed/NCBI View Article : Google Scholar
7	Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P and Mondelli V: The dietary pattern of patients with schizophrenia: A systematic review. J Psychiatr Res. 47:197–207. 2013.PubMed/NCBI View Article : Google Scholar
8	Polcwiartek C, Kragholm K, Rohde C, Hashemi N, Vang T and Nielsen J: Diabetic ketoacidosis and diabetes associated with antipsychotic exposure among a previously diabetes-naive population with schizophrenia: A nationwide nested case-control study. Diabetologia. 60:1678–1690. 2017.PubMed/NCBI View Article : Google Scholar
9	Leslie DL and Rosenheck RA: Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 161:1709–1711. 2004.PubMed/NCBI View Article : Google Scholar
10	Miron IC, Baroana VC, Popescu F and Ionica F: Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J. 40:12–17. 2014.PubMed/NCBI View Article : Google Scholar
11	Silvestre JS and Prous J: Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 27:289–304. 2005.PubMed/NCBI View Article : Google Scholar
12	Weston-Green K, Huang XF and Deng C: Second generation antipsychotic-induced type 2 diabetes: A role for the muscarinic M3 receptor. CNS Drugs. 27:1069–1080. 2013.PubMed/NCBI View Article : Google Scholar
13	Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA, et al: Pharmacogenetic associations of antipsychotic drug-related weight gain: A systematic review and meta-analysis. Schizophr Bull. 42:1418–1437. 2016.PubMed/NCBI View Article : Google Scholar
14	Goh KK, Chen CY, Wu TH, Chen CH and Lu ML: Crosstalk between schizophrenia and metabolic syndrome: The role of oxytocinergic dysfunction. Int J Mol Sci. 23(7092)2022.PubMed/NCBI View Article : Google Scholar
15	Cheng SC, Goh KK and Lu ML: Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. World J Psychiatry. 11:696–710. 2021.PubMed/NCBI View Article : Google Scholar
16	del Campo A, Bustos C, Mascayano C, Acuña-Castillo C, Troncoso R and Rojo LE: Metabolic syndrome and antipsychotics: The role of mitochondrial fission/fusion imbalance. Front Endocrinol (Lausanne). 9(144)2018.PubMed/NCBI View Article : Google Scholar
17	Vasiliu O: Case report: Cariprazine efficacy in young patients diagnosed with schizophrenia with predominantly negative symptoms. Front Psychiatry. 12(786171)2021.PubMed/NCBI View Article : Google Scholar
18	Mailman RB and Murthy V: Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr Pharm Des. 16:488–501. 2010.PubMed/NCBI View Article : Google Scholar
19	Vasiliu O, Vasile D and Voicu V: Efficacy and tolerability of antibiotic augmentation in schizophrenia spectrum disorders-A systematic literature review. Rom J Military Med. CXXIII:3–20. 2020.
20	Vasiliu O and Vasile D: Risk factors and quality of life in late-life depressive disorders. Rom J Military Med. CXIX:24–28. 2016.
21	Brown E, Wilding JPH, Barber TM, Alam U and Cuthbertson DJ: Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 20:816–828. 2019.PubMed/NCBI View Article : Google Scholar
22	Pereira MJ and Eriksson JW: Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 79:219–230. 2019.PubMed/NCBI View Article : Google Scholar
23	Lee PC, Ganguly S and Goh SY: Weight loss associated with sodium-glucose cotransporter-2 inhibition: A review of evidence and underlying mechanisms. Obes Rev. 19:1630–1641. 2018.PubMed/NCBI View Article : Google Scholar
24	Ribola FA, Cançado FB, Schouveri JH, De Toni VF, Medeiros VH and Feder D: Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 21:199–211. 2017.PubMed/NCBI
25	Frampton JE: Empagliflozin: A review in type 2 diabetes. Drugs. 78:1037–1048. 2018.PubMed/NCBI View Article : Google Scholar
26	Deeks ED and Scheen AJ: Canagliflozin: A review in type 2 diabetes. Drugs. 77:1577–1592. 2017.PubMed/NCBI View Article : Google Scholar
27	Dhillon S: Dapagliflozin: A review in type 2 diabetes. Drugs. 79:1135–1146. 2019.PubMed/NCBI View Article : Google Scholar
28	Liu L, Shi FH, Xu H, Wu Y, Gu ZC and Lin HW: Efficacy and safety or ertugliflozin in type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 12(752440)2022.PubMed/NCBI View Article : Google Scholar
29	Shi Y, Si Y, Fu R, Zhang M, Jiang K, Dai W, Shen J, Li X and Yuan Y: Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: A meta-analysis of randomized controlled trials. Endokrynol Pol. 73:71–80. 2022.PubMed/NCBI View Article : Google Scholar
30	Cho YK, Kim YJ and Jung CH: Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: A systematic review and a meta-analysis. J Obes Metab Syndr. 30:336–344. 2021.PubMed/NCBI View Article : Google Scholar
31	Ashraf GM, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO and Tarazi FI: Empagliflozin effectively attenuates olanzapine-induced body weight gain in female Wistar rats. Front Pharmacol. 12(578716)2021.PubMed/NCBI View Article : Google Scholar
32	Cooper SJ and Reynolds GP: With expert co-authors (in alphabetical order). Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, et al: BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 30:717–748. 2016.PubMed/NCBI View Article : Google Scholar
33	Lally J, O'Loughlin A, Stubbs B, Guerandal A, O'Shea D and Gaughran F: Pharmacological management of diabetes in severe mental illness: A comprehensive clinical review of efficacy, safety, and tolerability. Expert Rev Clin Pharmacol. 11:411–424. 2018.PubMed/NCBI View Article : Google Scholar
34	Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A and Hahn MK: Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. J Endocrinol. 227:71–81. 2015.PubMed/NCBI View Article : Google Scholar
35	Luo C, Wang X, Huang H, Mao X, Zhou H and Liu Z: Effect of metformin on antipsychotic-induced metabolic dysfunction: The potential role of gut-brain axis. Front Pharmacol. 10(371)2019.PubMed/NCBI View Article : Google Scholar
36	Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY and Shin SJ: Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget. 9:5416–5423. 2017.PubMed/NCBI View Article : Google Scholar
37	Barbosa M and Fernandes V: Rapid-onset clozapine-induced hyperglycemia: Pathways of glycaemic dysregulation. BMJ Case Rep. 14(e243938)2021.PubMed/NCBI View Article : Google Scholar
38	Foldemo A, Wӓrdig R, Bachrach-Lindström M, Edman G, Holmberg T, Lindström T, Valter L and Osby U: Health-related quality of life and metabolic risk in patients with psychosis. Schizophr Res. 152:295–299. 2014.PubMed/NCBI View Article : Google Scholar
39	Agarwal SM and Stogios M: Cardiovascular health in severe mental illness: Potential role for metformin. J Clin Psychiatry. 83(22ac14419)2022.PubMed/NCBI View Article : Google Scholar
40	Lao X, Ye H and Si T: A review of switching strategies for patients with schizophrenia comorbid with metabolic syndrome or metabolic abnormalities. Neuropsychiatr Dis Treat. 17:453–469. 2021.PubMed/NCBI View Article : Google Scholar
41	Halimi S and Vergès B: Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 40 (Suppl.1):S28–S34. 2014.PubMed/NCBI View Article : Google Scholar